Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom.
Aged
Aged, 80 and over
Clinical Decision-Making
Combined Modality Therapy
Cytogenetic Analysis
Disease Management
Europe
/ epidemiology
Female
France
Germany
Humans
Italy
Male
Middle Aged
Multiple Myeloma
/ diagnosis
Outcome Assessment, Health Care
Practice Patterns, Physicians'
Prognosis
Retreatment
Retrospective Studies
Treatment Outcome
United Kingdom
clinical practice patterns
medical records
multiple myeloma
retrospective studies
treatment outcomes
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
18
02
2020
revised:
08
05
2020
accepted:
12
05
2020
pubmed:
18
5
2020
medline:
17
6
2021
entrez:
18
5
2020
Statut:
ppublish
Résumé
The treatment paradigm in newly diagnosed multiple myeloma (NDMM) is evolving toward individualized, risk-directed, and longer duration of therapy (DOT). The objective of this study was to describe treatment patterns and outcomes in non-transplant NDMM in four European countries. This retrospective chart review included adults with NDMM diagnosed between January 1, 2012, and December 31, 2013 (early cohort), or April 1, 2016, and March 31, 2017 (recent cohort). Among 836 patients, molecular testing was performed in 21% and 35% patients of early vs recent cohorts; proteasome inhibitor (PI)/alkylator combinations were the principal first-line (1 L) therapy (39% vs 43%). Use of immunomodulatory drug (IMID)/alkylator combinations declined from early to recent cohort (26% vs 13%) but IMID (7% vs 16%) use increased. Few patients (5%) received 1 L maintenance therapy. Two-thirds of patients were treated with a fixed duration intent, with a median 7-month 1 L DOT and progression-free survival (PFS) of 32.8 months in the early cohort. Both 1 L DOT and PFS were longer with oral compared to injectable regimens. Although frontline treatment patterns changed significantly, 1 L DOT is short. The uptake of molecular testing and 1 L maintenance is low. These results highlight areas of unmet need in NDMM.
Identifiants
pubmed: 32418256
doi: 10.1111/ejh.13439
pmc: PMC7497114
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
308-325Subventions
Organisme : Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
ID : N/A
Informations de copyright
© 2020 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.
Références
J Clin Oncol. 2015 Oct 20;33(30):3459-66
pubmed: 26282661
N Engl J Med. 2018 Feb 8;378(6):518-528
pubmed: 29231133
N Engl J Med. 2014 Sep 4;371(10):906-17
pubmed: 25184863
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Korean J Intern Med. 2016 Sep;31(5):809-19
pubmed: 27604793
Eur J Haematol. 2020 Sep;105(3):308-325
pubmed: 32418256
Blood. 2016 Jun 16;127(24):2955-62
pubmed: 27002115
N Engl J Med. 2012 May 10;366(19):1759-69
pubmed: 22571200
Leukemia. 2019 Feb;33(2):546-549
pubmed: 30267010
Health Policy. 2015 Feb;119(2):186-94
pubmed: 25476554
J Manag Care Spec Pharm. 2018 Oct;24(10):1019-1026
pubmed: 30247101
Blood. 2008 Mar 1;111(5):2516-20
pubmed: 17975015
Blood Cancer J. 2018 Nov 9;8(11):109
pubmed: 30413684
Blood. 2015 Mar 26;125(13):2068-74
pubmed: 25628469
Crit Rev Oncol Hematol. 2018 Jan;121:74-89
pubmed: 29279102
PLoS One. 2018 Dec 5;13(12):e0208507
pubmed: 30517181
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Ann Hematol. 2012 Jun;91(6):875-88
pubmed: 22476884
Oncotarget. 2017 Jul 15;8(36):60656-60672
pubmed: 28948001
Cancer Invest. 2015;33(10):496-504
pubmed: 26506456
Ann Oncol. 2017 Jul 1;28(suppl_4):iv52-iv61
pubmed: 28453614
Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120
pubmed: 26951748
Pharmacoecon Open. 2020 Sep;4(3):473-483
pubmed: 31605300
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):212-222
pubmed: 29222258
J Clin Oncol. 2014 Feb 20;32(6):587-600
pubmed: 24419113
Haematologica. 2015 May;100(5):e207-10
pubmed: 25596270
Br J Haematol. 2014 Mar;164(5):684-93
pubmed: 24313224
N Engl J Med. 2019 May 30;380(22):2104-2115
pubmed: 31141632
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Curr Oncol. 2014 Aug;21(4):e573-603
pubmed: 25089109
Blood. 2018 Jan 18;131(3):301-310
pubmed: 29150421
Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):575-583.e2
pubmed: 28886839
Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):8-17.e16
pubmed: 31722839
Lancet. 2017 Feb 4;389(10068):519-527
pubmed: 28017406
Mayo Clin Proc. 2010 Mar;85(3):225-30
pubmed: 20194150
Blood. 2012 May 10;119(19):4375-82
pubmed: 22422823
Haematologica. 2014 Feb;99(2):232-42
pubmed: 24497560
Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):e401-e419
pubmed: 30030033
PLoS One. 2018 May 1;13(5):e0196596
pubmed: 29715281